Treatment Effect of Bevacizumab as First-line Therapy for MBC (Mainly HER2-Negative)
{"Image DocumentName": "Treatment Effect of Bevacizumab as First-line Therapy for MBC (Mainly HER2-Negative)", "Image ImageDescription": "Chemotherapy alone/plus placebo. Chemotherapy plus bevacizumab. Response Rate. P< \u2020 P = P< \u2020   P = \u2020 E AVADO2. RIBBON-13.   Chemotherapy alone vs chemotherapy plus 10 mg/kg bevacizumab. \u2020 Chemotherapy plus placebo vs chemotherapy plus 15 mg/kg bevacizumab. 1. Miller et al. N Engl J Med. 2001;357(26): Miles et al. J Clin Oncol May 24 [Epub ahead of Print]. 3. Robert et al. J Clin Oncol. 2009;27(15S). Abstract 1005.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}